New Drug Protects Mitochondria and Prevents Kidney Injury in Mice

Nov 12, 2025

Media Contact:

Sophia Friesen
Manager, Research Communications, �鶹ѧ��Ʒ��
Email: sophia.friesen@hsc.utah.edu

Serious damage to short-term kidney function—known as acute kidney injury, or AKI—can be fatal and also increase the risk of irreversible chronic kidney disease. It can be triggered by stressors ranging from sepsis to heart surgery, and it affects more than half of ICU patients. There are currently no drugs to treat AKI.

Now, researchers at �鶹ѧ��Ʒ�� (U of U Health) have found that AKI is triggered by fatty molecules called ceramides, which cause serious injury by damaging kidney mitochondria. Using a backup drug candidate that changes ceramide metabolism, the team was able to preserve mitochondrial integrity and prevent kidney injury in mice.

“We completely reversed the pathology of acute kidney injury by inactivating ceramides,” says distinguished professor and Chair of the Department of Nutrition and Integrative Physiology in the University of Utah College of Health and senior author on a paper describing the results. “We were stunned—not only did kidney function stay normal, but the mitochondria were unscathed,” Summers says. “It was truly remarkable.”

Key points:

Acute kidney injury (AKI) is a serious and common reaction to many severe health stressors, including heart surgery.
New research in mice found that molecules called ceramides trigger AKI by damaging mitochondria.
A ceramide-lowering drug protected mitochondria and prevented AKI in mice.

IMPACT: If the drug works in people, it could prevent kidney injury in high-risk populations, or potentially even treat other diseases that affect mitochondria, like heart failure and diabetes.

Electron microscope images of mitochondria. Left: healthy mitochondria. Middle: badly damaged mitochondria from a kidney with AKI. Right: mitochondria treated with a drug that prevents AKI. Image credit: Rebekah Nicholson and Linda Nikolova

An early warning sign for kidney injury

The Summers lab had previously shown that ceramides can damage tissues ranging from heart to liver. When the team profiled ceramides in models of AKI, the correlation was striking: ceramide levels spiked sharply after kidney injury in both mice and human urine samples.

“Ceramide levels are very elevated in kidney injury,” says first author on the study, who did the research as a graduate student in nutrition and integrative physiology at U of U Health and is now a postdoctoral fellow at the Arc Institute. “They go up quickly after damage to the kidneys, and they go up in relation to the severity of the injury. The worse the kidney injury is, the higher the ceramide levels will be.”

These findings suggest that urinary ceramide levels could serve as an early biomarker for AKI, helping doctors identify patients at risk—such as those undergoing heart surgery—before symptoms appear. “If patients are undergoing a procedure that we know puts them at high risk of AKI, then we can better predict whether or not they're actually going to have one,” Nicholson says.

Rebekah Nicholson, PhD, lead author on the study. Image credit: Rebekah Nicholson.

Modifying ceramides prevents kidney injury

The researchers were able to almost completely prevent kidney injury in an animal model by changing how ceramides are made. By making a precise genetic change that affects ceramide production, the team created “super mice” that don’t get AKI, even in conditions that would otherwise trigger it.

Similarly, pre-treating mice with a new ceramide-lowering drug candidate developed by Centaurus Therapeutics, a company co-founded by Summers, prevented kidney injury. Kidney function improved, mice stayed fully active, and the kidneys looked nearly normal under the microscope. The model the researchers use tends to put the kidneys under a lot of stress, Nicholson says, so “it’s really remarkable that mice were protected from the injury.”

“These mice looked incredible,” Summers adds.

Ceramides cause kidney injury by damaging mitochondria, the part of the cell that produces energy, the researchers found. Mitochondria in injured kidney cells are visibly malformed under a microscope, and they can’t produce energy as efficiently. Tweaking how ceramides are made, either genetically or with the drug, kept mitochondria healthy and functional even under stress.

Fluorescent microscope image of the proximal tubule, the part of the kidney that’s most affected by ceramides. Image credit: Luis Cedeño-Rosario

Hope for acute kidney injury and other diseases

Scott Summers, PhD, senior author on the study. Image credit: Kristan Jacobsen Photography / �鶹ѧ��Ʒ��.

Summers emphasizes that the compound used in the study is closely related to, but not the same as, the ceramide-lowering drug that has advanced into human clinical testing. Results in mice don’t always translate directly to humans, he notes, and additional studies are needed to establish safety.

“We’re thrilled by how protective this backup compound was, but it’s still preclinical,” Summers says. “We need to be cautious and do our due diligence to make sure this approach is truly safe before moving it into patients.”

But the researchers are optimistic. If the results hold true in humans, the researchers hope that the drug could be provided in advance to people at high risk of acute kidney injury—such as people undergoing heart surgery, about a quarter of whom experience AKI.

Because the drug seems to work by keeping mitochondria healthy, the researchers suspect that it might help treat or prevent many other diseases that affect mitochondria.

“Mitochondrial problems show up in so many diseases—heart failure, diabetes, fatty liver disease,” Summers says. “So if we can truly restore mitochondrial health, the implications could be enormous.”

###

The results are published in Cell Metabolism as “”

The work was supported by a NCRR Shared Instrument Grant, the Kidney Precision Medicine Project, the National Institutes of Health, including the National Cancer Institute (grants P30CA042014, CA272529), the National Institute of Diabetes and Digestive and Kidney Diseases (grants DK115824, DK116888, DK116450, DK130296, DK108833, DK112826, 1F31DK134088 and 5T32DK091317), the National Institute of General Medical Sciences (grants 3R35GM131854 and 3R35GM131854-04S1), the Juvenile Diabetes Research Foundation (JDRF 3-SRA-2019-768-A-B and JDRF 3-SRA-2019-768-A-B to WLH), the Burroughs Wellcome Fund for Postdoctoral Diversity Enrichment Program (1058616), the American Diabetes Association, the American Heart Association, the Margolis Foundation, and the University of Utah Diabetes and Metabolism Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Scott Summers and Jeremy Blitzer are co-founders and shareholders of Centaurus Therapeutics. Liping Wang is a shareholder of Centaurus Therapeutics. DN and Blitzer are listed as inventors on US Patents 1177684, 11597715, and 11135207 licensed to Centaurus Therapeutics, Inc.

�鶹ѧ����Ʒ��